Karolinska Development
Karolinska Development is a Nordic life sciences investment company based in Solna, Sweden. The company focuses on identifying and investing in medical innovations, particularly in therapeutic and MedTech companies. Its business model involves financing these companies until they achieve proof-of-concept or positive operating profit, after which exit options are evaluated. The portfolio consists of companies developing treatments for severe diseases, with several drug candidates in various clinical trial phases.
Fiscal year 2024 · change from previous year
Development 2019–2024
Business
Share of revenueInvestments in companies developing innovative treatments for severe diseases.
Investments in medical technology companies until they achieve positive operating profit.
Agreements with acquirers for milestone payments during drug development and commercialization.
Customers
Karolinska Development primarily collaborates with professional life science investors and syndicates to co-invest in promising therapeutic and MedTech companies. Its customer base includes pharmaceutical companies interested in acquiring or licensing drug candidates that have demonstrated proof-of-concept. The company also engages with MedTech firms seeking financial support until they reach profitability. These collaborations are crucial for advancing clinical trials and achieving successful exits through divestments or licensing agreements.
Co-invest in therapeutic and MedTech companies to share risk and reward.
Acquire or license drug candidates after proof-of-concept is demonstrated.
Receive financial support until achieving positive operating profit.
Strategy
Karolinska Development's strategic priorities include enhancing the value of its portfolio companies through clinical advancements and strategic exits. The company aims to support its therapeutic and MedTech investments until they reach significant milestones, such as proof-of-concept or profitability. It is also focused on strengthening its financial position through strategic divestments and licensing agreements. These priorities are essential for maintaining a robust investment portfolio and achieving attractive returns for shareholders.
To achieve significant clinical milestones and strategic exits.
To ensure liquidity and support future investments.
Geography
Karolinska Development is headquartered in Solna, Sweden, and operates primarily within the Nordic region. Its investments are focused on companies that are based in or have significant operations in Europe. The company also has a presence in the United States through partnerships and sales offices, particularly for MedTech products. This geographic focus allows Karolinska Development to leverage regional expertise and networks to support its portfolio companies effectively.
Risks
Karolinska Development faces several risks, including the inherent uncertainties of clinical trials and regulatory approvals. The success of its portfolio companies is contingent on achieving positive trial results and obtaining necessary market approvals. Market conditions and competitive pressures in the life sciences sector can also impact the company's ability to execute successful exits. Additionally, geopolitical and economic factors, such as changes in healthcare regulations or funding availability, pose risks to investment returns.
Success depends on positive trial outcomes and regulatory approvals.
Competitive pressures and market dynamics affect exit opportunities.
Accounting
Judgemental itemsImpacts reported income and asset values through valuation models.
Impact: high
Affects financial results from divestments and licensing agreements.
Impact: medium
Similar listed companies
Publicly listed companies with a comparable business focus.
Skanska
SKA-B · Industrials
Skanska AB is a global construction and project development company headquartered in Sweden.
Korsana Biosciences, Inc.
KRSA · Pharmaceutical Preparations
Carasent
CARA · Health Care
Carasent is a Swedish company specializing in digital services for the healthcare industry.
Nordicus Partners Corp
NORD · Services-Management Consulting Services
Nordicus Partners Corp is a U.S.-listed business accelerator and holding company focused on Nordic life sciences ventures.
Nkarta, Inc.
NKTX · Pharmaceutical Preparations
Greenland Mines Ltd
GRMLW · Biological Products, (No Diagnostic Substances)
Greenland Mines Ltd is a U.S.-based development-stage life sciences company that has not yet generated operating revenue.
Last updated: 24/09/2026